If you invested in R1 RCM and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses »

CLASS PERIOD
N/A

LEAD PLAINTIFF DEADLINE
N/A

STOCK SYMBOL
NASDAQ: RCM

CONTACT
844-916-0895
RCM@hbsslaw.com

 

The investigation focuses on the propriety of R1 RCM’s financial disclosures.

On Oct. 16, 2023, financial fraud investigator Jehoshaphat Research published a scathing forensic report accusing R1 RCM of engaging in misrepresentative accounting and calling its stock “practically uninvestible today.”

Among other matters, Jehoshaphat accused R1 RCM of engaging in “aggressive mark-to-model revenue recognition creating most of the revenue growth in the company today, creatively deflat[ing] expenses that inflate Adjusted EBITDA by approximately 55%, potentially systematic under-reserving for customer bad debts” and “increasingly aggressive revenue recognition practices to pull forward revenues[.]”

In response, the price of R1 RCM shares fell about 8% on Oct. 16, 2023.

Media Images
Image

Hagens Berman purchases advertisements on search engines, social media sites and other websites. Transmission of the information contained or available through this website is not intended to create, and receipt does not constitute, an attorney-client relationship. If you seek legal advice or representation by Hagens Berman, you must first enter a formal agreement. All information contained in any transmission is confidential and Hagens Berman agrees to protect information against unauthorized use, publication or disclosure. This site is regulated by the Washington Rules of Professional Conduct.